Naveena Singh

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

Ian Jacobs, Usha Menon, Andy Ryan et al. · The Lancet · 2015 · 1.1K citations · Full text

Medicine, Gynecology, Oncology +14

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia León‐Castillo, Stephanie M. de Boer, Melanie Powell et al. · Journal of Clinical Oncology · 2020 · 837 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

Usha Menon, Aleksandra Gentry‐Maharaj, Rachel Hallett et al. · The Lancet Oncology · 2009 · 834 citations · Full text

Medicine, Gynecology, Oncology +17

Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

Usha Menon, Aleksandra Gentry‐Maharaj, Matthew Burnell et al. · The Lancet · 2021 · 700 citations · Full text

Medicine, Gynecology, Oncology +17

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 623 citations · Full text

Medicine, Oncology, Radiation Oncology +17